Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsShares IssuedShares Outstanding
Ratios

Keros Therapeutics (KROS) Accumulated Depreciation & Amortization (2019 - 2024)

Historic Accumulated Depreciation & Amortization for Keros Therapeutics (KROS) over the last 6 years, with Q4 2024 value amounting to $2.9 million.

  • Keros Therapeutics' Accumulated Depreciation & Amortization rose 7145.35% to $2.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.9 million, marking a year-over-year increase of 7145.35%. This contributed to the annual value of $2.9 million for FY2024, which is 7145.35% up from last year.
  • As of Q4 2024, Keros Therapeutics' Accumulated Depreciation & Amortization stood at $2.9 million, which was up 7145.35% from $1.7 million recorded in Q4 2023.
  • Keros Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $2.9 million during Q4 2024, with a 5-year trough of $721000.0 in Q4 2020.
  • Its 5-year average for Accumulated Depreciation & Amortization is $1.5 million, with a median of $1.2 million in 2022.
  • Per our database at Business Quant, Keros Therapeutics' Accumulated Depreciation & Amortization surged by 1733.7% in 2021 and then surged by 7145.35% in 2024.
  • Keros Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $721000.0 in 2020, then grew by 17.34% to $846000.0 in 2021, then surged by 37.47% to $1.2 million in 2022, then skyrocketed by 47.89% to $1.7 million in 2023, then soared by 71.45% to $2.9 million in 2024.
  • Its last three reported values are $2.9 million in Q4 2024, $1.7 million for Q4 2023, and $1.2 million during Q4 2022.